Daiichi Arbitration Case Bares Trail Of Deception At Ranbaxy
Executive Summary
Incriminating details in an arbitration order against the former Ranbaxy top brass led by the Singh brothers has put the spotlight back on allegations of misrepresentation of critical information concerning the US Department of Justice (DoJ) and FDA investigations against the Indian company at the time of its takeover by Daiichi Sankyo. The Singh brothers, who have challenged the award, though, have cried foul, questioning the timing of the apparent leak of the "confidential" award ahead of a court hearing.
You may also be interested in...
IPA's Jain On The Journey So Far And Fires To Douse
Sudarshan Jain, the new secretary general of the Indian Pharmaceutical Alliance and ex-Abbott managing director, wears many hats, including that of a senior advisor with a private equity advisory firm. He recounts having “survived in different cultures” in his career and outlines the priorities in his new role, amid continuing questions around generic quality.
Christmas Cheer For Daiichi, Another Win Vs Ranbaxy Brothers
Daiichi Sankyo has secured another favorable ruling in Singapore in a case pertaining to the enforcement of the INR35bn arbitration award against the sparring Singh brothers of Ranbaxy, piling more pressure on the duo. An appeal remains an option.
Singh Brothers Asked To Pay Up $550m Arbitral Award To Daiichi
An Indian court has ruled that tycoons Malvinder and Shivinder Singh must pay Daiichi Sankyo $550m in damages originally awarded by a Singapore arbitration panel over the Japanese drugmaker’s ill-fated purchase of generic giant Ranbaxy.